[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Asan Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":597},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,45,75,97,120,151,175,206,231,250,266,283,302,323,344,368,391,413,434,456,480,501,524,549,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100501329","clinical-impact-of-intravascular-ultrasound-based-artificial-intelligence-technologies-innovate-pci-100501329",false,"NCT05807841","Clinical Impact of Intravascular Ultrasound-Based Artificial Intelligence Technologies (INNOVATE-PCI)","Influence of Novel Intravascular Ultrasound-Based Artificial Intelligence Technologies on Event Reduction Following Percutaneous Coronary Intervention (INNOVATE-PCI)","Inclusion Criteria:\n\n* Age 19 years or older\n* Symptomatic angina patients with objective myocardial ischemia\n* Patients with at least one major epicardial coronary artery that requires stent implantation\n* Subject who signs with informed consent form\n\nPatient exclusion Criteria:\n\n* ST-segment elevation MI at admission\n* Patients who underwent coronary artery bypass surgery or heart transplantation\n* Left ventricular ejection fraction \\\u003C30%\n* Cardiogenic shock\n* Patients whose life expectancy \\\u003C2 years\n* Woman who are breastfeeding, pregnant or planning to become pregnant during study\n* Patients in whom anti-platelets or heparin is contraindicated\n\nLesion exclusion Criteria:\n\n* Left main culprit lesion (angiographic diameter stenosis \\>50%)\n* Thrombus-containing lesion\n* In-stent restenosis\n* Side branch lesion\n* Chronic total occlusion\n* Small vessel with reference diameter \\\u003C2.5mm\n* Coronary spasm despite administration of nitrate\n* Inability for imaging catheter to pass through tight stenosis, calcification, angulations\n* Poor image quality\n* Angiographically visible collateral vessels","ALL","19 Years",{"count":20,"type":21},3000,"ESTIMATED","OBSERVATIONAL","This study is a prospective, multicenter study in the real practice to validate the diagnostic performances and clinical impact of coronary angiography \\& intravascular ultrasound (IVUS)-based models developed by machine learning (ML).",[25],"Coronary Artery Disease",[27,28,29,30,31],"percutaneous coronary intervention","artificial intelligence","machine learning","intravascular ultrasound","coronary angiography","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":36},"2020-02-20",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Asan Medical Center","OTHER",16,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100644487","blood-based-minimal-residual-disease-in-advanced-epithelial-ovarian-cancer-after-1st-line-therapy-100644487","NCT07670962","Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy","The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy","Inclusion Criteria:\n\nWomen aged 19 years or older. Pathologically confirmed high-grade serous, endometrioid, clear cell, or mixed type ovarian cancer.\n\nFIGO stage III or IV. Patients who have completed primary debulking surgery (PDS) or interval debulking surgery (IDS) and platinum-based chemotherapy (subsequent maintenance therapy, such as bevacizumab or PARP inhibitors, is allowed).\n\nPatients showing radiological or clinical Complete Response (CR) after the completion of platinum-based chemotherapy.\n\nWritten informed consent for the study.\n\nExclusion Criteria:\n\nRadiological progressive disease during or immediately after treatment. Expected survival of 3 months or less. Immunodeficiency or pathological bleeding tendencies. Unable to undergo blood tests or unwilling to undergo repeated blood sampling. Concurrent other solid tumors or history of malignant tumors within the last 5 years.\n\nRefusal to consent to participate in this study.","FEMALE",{"count":54,"type":21},300,"3 Years","The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.\n\nResearchers are inviting women who have been diagnosed with stage III or IV epithelial ovarian cancer and have recently completed their first-line treatments, which include surgery and platinum-based chemotherapy.\n\nThe study focuses on \"circulating tumor DNA\" (ctDNA), which are tiny fragments of genetic material that cancer cells release into the bloodstream as they break down. Finding these DNA fragments in the blood when a patient appears to be cancer-free on standard tests is known as assessing for minimal residual disease (MRD).\n\nBecause this is an observational study, participants will receive standard medical care as directed by their doctor. For the research portion, participants will provide blood samples at specific times: at the time of diagnosis, shortly after surgery, right after finishing their first-line chemotherapy, and then every 3 months during regular follow-up visits. Researchers will also analyze a sample of the tumor tissue that was already removed during the patient's standard surgery.\n\nBy tracking these participants for up to 3 years, researchers hope to discover if the ctDNA test can accurately identify patients who have a high risk of their cancer returning, and if it can detect this earlier than traditional imaging scans or standard blood tests like CA-125.",[58,59,60],"Ovarian Neoplasms","Carcinoma, Ovarian Epithelial","Ovarian Cancer",[62,63,64,65],"ctDNA","Minimal Residual Disease","MRD","Liquid Biopsy","NOT_YET_RECRUITING","2026-06-22",{"date":69,"type":36},"2026-06-26",{"date":71,"type":21},"2026-07-01",{"date":73,"type":21},"2028-12-31",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100471413","phase-4-tailored-versus-coventional-antiplatelet-strategy-intended-after-optimized-drug-eluting-stent-100471413","NCT05418556","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug","OPTIMIZE-APT","Inclusion Criteria:\n\n1. Men or women ≥19 years\n2. Typical chest pain or objective evidence of myocardial ischemia suitable for PCI\n3. Significant de novo coronary artery lesions suitable for DES implantation\n4. Patients who underwent optimized stent implantation either by IVUS or OCT\n\n   * Using IVUS\n\n     * MSA \\>5.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * Plaque burden \\\u003C50% with 5 mm of both stent edge\n     * No edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n   * Using OCT\n\n     * MSA \\>4.5 mm2, or MSA \\>90% of the MLA at the distal reference segment\n     * No significant malapposition\n     * No significant edge dissection, thrombus or plaque protrusion\u002Fstent area \\\u003C10%\n5. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site\n\nExclusion Criteria:\n\n1. Angiographic exclusion criteria: any of the followings 1. Bypass graft lesions 2. Lesions in which impaired delivery of imaging catheters is expected:\n\n   * Extreme angulation (≥90°) proximal to or within the target lesion.\n   * Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.\n   * Heavy calcification proximal to or within the target lesion.\n2. In-stent restenosis\n3. Hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.\n4. Persistent thrombocytopenia (platelet count \\\u003C80,000\u002Fl)\n5. Any history of hemorrhagic stroke or intracranial hemorrhage \u002F TIA or ischemic stroke within the past 6 months\n6. A known intolerance or hypersensitivity to a study drug (aspirin, clopidogrel or ticagrelor) or heparin\n7. Patients requiring long-term oral anticoagulants or cilostazol\n8. Any surgery requiring general anesthesia or discontinuation of aspirin and\u002For an ADP antagonist is planned within 12 months after the procedure.\n9. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.\n10. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.\n11. History of liver cirrhosis (Child-Pugh B or C) or biliary tract obstruction\n12. Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes\n13. Cardiogenic shock at the index admission\n14. Patient's pregnant or breast-feeding\n15. Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high risk for bleeding, malignancies with a high risk for bleeding)\n16. Unwillingness or inability to comply with the procedures described in this protocol.",{"count":84,"type":21},3944,"INTERVENTIONAL",[87],"PHASE4","Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)\n\nHypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS\u002FOCT could act as an essential criterion for decision making for tailored antithrombotic strategy)",[25],{"date":35,"type":36},{"date":92,"type":36},"2022-10-21",{"date":94,"type":21},"2032-12-31",{"name":42,"class":43},33,{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":85,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100586333","phase-3-circulating-tumor-dna-mrd-guided-adjuvant-therapy-for-curatively-resected-locally-advanced-esophageal-squamous-cell-carcinoma-100586333","NCT06914011","Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","Multi-center, Randomized, Phase III Trial of Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (MRD2START)","MRD2START","Inclusion Criteria:\n\n* 1\\. Be willing and able to provide written informed consent. 2. Be ≥19 years of age on the day of signing the informed consent form. 3. Have ECOG performance status of 0 or 1 (Appendix 1). 4. Have a histologically confirmed diagnosis of squamous cell carcinoma of the esophagus\n\n  * Patients with tumors of mixed histology (i.e., squamous and non-squamous) are eligible if the predominant histological component is squamous, except when small cell or neuroendocrine elements are present.\n\n    5\\. Must have completed surgical resection for localized disease, either with prior neoadjuvant therapy (chemotherapy or chemoradiotherapy) or without prior neoadjuvant therapy (i.e., upfront surgery), in accordance with the 8th edition of the AJCC staging system (Appendix 2). Exceptionally, cases with supraclavicular lymph node metastasis as the only M1 lesion are also eligible if the lymph node has been surgically removed.\n\n    6\\. Must have undergone curative surgery (R0 resection) with negative margins on the resected specimen.\n\n    7\\. Complete resection must have been performed between 4-16 weeks before randomization.\n\n    8\\. Must have a documented disease-free status based on a complete physical examination and imaging studies within 4 weeks before randomization. Imaging studies must include CT scans (or MRI) of the chest, abdomen, and pelvis.\n\n    9\\. Must provide tumor tissue from pre-treatment biopsy (i.e., a biopsy obtained prior to neoadjuvant therapy in cases where neoadjuvant therapy is followed by surgery) or from surgical specimens and baseline blood samples for post-surgery ctDNA-MRD measurement and biomarker analyses.\n  * For patients who underwent upfront surgery, surgical tissue is preferred.\n  * For those who received neoadjuvant therapy followed by surgery, pre-treatment biopsy tissue is required. If pre-treatment biopsy tissue is unavailable or inadequate, submission of surgical specimens may be permitted following approval by the Study Sponsor.\n  * A FFPE tumor specimen in a paraffin block or 20 (at least 10, with a thickness of 10 µm) freshly cut unstained FFPE slides, along with one H\\&E-stained slide, must be submitted with the associated pathology report. If an insufficient number of slides is available, the decision on patient enrollment can be made in consultation with the Study Sponsor.\n  * Peripheral blood of approximately 4 mL must be collected for germline DNA analysis.\n  * Peripheral blood of approximately 20 mL must be collected between 3 to 12 weeks after curative surgery for ctDNA testing.\n\n    10\\. Must be confirmed to have MRD-positive status via postoperative baseline ctDNA testing.\n\n    11\\. Must have adequate major organ functions as demonstrated by the following laboratory results obtained within 14 days before randomization (these criteria must also be met within 7 days before initiating study treatment in the adjuvant therapy arm):\n  * Adequate bone marrow function defined by:\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FμL without granulocyte colony-stimulating factor support within 7 days before laboratory testing\n* Platelet count ≥ 100 ×103\u002FμL without transfusion within 7 days before laboratory testing\n\n  * Adequate renal function defined by:\n* Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 50 mL\u002Fminute, calculated using the Cockcroft-Gault formula (Appendix 3) or measured by a 24-hour urine collection\n\n  • Adequate hepatic function defined by:\n* ALT and AST ≤ 2.5 × ULN\n* Total bilirubin ≤ 1.5 × ULN, except for subjects with Gilbert syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who must have a total bilirubin level ≤ 3 × ULN 12. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to randomization. If the urine test is positive or inconclusive, a serum pregnancy test will be required.\n\n  13\\. Female subjects of childbearing potential randomized to the adjuvant therapy arm must agree to use an adequate method of contraception for the duration of study treatment and for 90 days after the last dose of study treatment.\n\n  14\\. Non-sterile male subjects randomized to the adjuvant therapy arm with female sexual partner(s) of childbearing potential must agree to use an adequate method of contraception for the duration of study treatment and for 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* 1\\. Documented recurrence of esophageal cancer before randomization following curative resection.\n\n  2\\. Receipt of any treatment aimed at the resected esophageal cancer after curative surgery, including chemotherapy, targeted therapy, immunotherapy, radiotherapy, biologic therapy, investigational agent, or local therapies, except for procedures intended for palliative care (e.g., stent insertion, balloon dilatation, or feeding enterostomy).\n\n  3\\. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor, or any other drug targeting T-cell co-stimulation or checkpoint pathways.\n\n  4\\. Active autoimmune disease requiring systemic treatment within the 2 years prior to study entry (i.e., using disease-modifying agents, corticosteroids, or immunosuppressive drugs).\n  * Replacement therapy (e.g., thyroxine for autoimmune-related hypothyroidism, insulin for type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n\n    5\\. Condition requiring systemic treatment with corticosteroids (\\>10 mg daily prednisone or equivalent) or any other form of immunosuppressive therapy within 14 days prior to study entry.\n  * Use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids is permitted if there is no active autoimmune disease.\n  * A short course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergens) is permitted.\n\n    6\\. Receipt of a live vaccine within 28 days prior to study entry.\n  * COVID-19 vaccines are allowed except for any live vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.\n\n    7\\. Active infection requiring systemic therapy within 14 days prior to study entry.\n\n    8\\. History of severe hypersensitivity to paclitaxel, carboplatin, or any antibody products.\n\n    9\\. Known history of, or any evidence of, interstitial lung disease, non-infectious pneumonitis, or pulmonary fibrosis diagnosed based on imaging or clinical findings.\n  * Subjects with radiation pneumonitis may be enrolled if radiation pneumonitis is stable (beyond the acute phase) and unlikely to recur.\n\n    10\\. History of allogeneic stem cell or solid organ transplantation. 11. Malignancies other than esophageal cancer within the 3 years prior to study entry, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ (e.g., cervix, breast, or prostate).\n  * Subjects who received endoscopic mucosal resection or dissection for superficial mucosal cancers within the past 3 years are eligible.\n\n    12\\. Subjects with toxicities attributed to prior anti-cancer therapy, except alopecia, anorexia, fatigue, and hearing loss, that have not resolved to Grade 1 (NCI CTCAE v5.0) or baseline before randomization will be excluded.\n\n    13\\. Significant cardiovascular impairment within 6 months prior to study entry, including a history of congestive heart failure (New York Heart Association Class III or IV), unstable angina, myocardial infarction, cerebrovascular accident, or cardiac arrhythmia associated with hemodynamic instability.\n\n    14\\. Any serious or uncontrolled medical disorder that, in the investigator's opinion, may increase the risk associated with study participation or study treatment administration, or compromise the subject's ability to receive protocol therapy.\n\n    15\\. History or current evidence of any condition, therapy, or laboratory abnormality that could confound trial results, interfere with the subject's participation for the full trial duration, or is not in the best interest of the subject to participate, in the investigator's opinion.\n\n    16\\. Medical or psychiatric conditions that impair the subject's ability to give informed consent or complete the protocol, or a history of non-compliance.\n\n    17\\. Known history of Human Immunodeficiency Virus (HIV) infection. 18. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA ≥500 IU\u002FmL (or 2,500 copies\u002FmL), or active hepatitis C virus (HCV) infection:\n  * Subjects with chronic hepatitis B (HBV DNA \\\u003C 500 IU\u002FmL or \\\u003C 2,500 copies\u002FmL) who are receiving antiviral therapy can be enrolled. Patients with detectable HBsAg or detectable HBV DNA should be managed according to institutional guidelines.\n  * Patients with a negative HCV antibody test result at screening or a positive HCV antibody test followed by a negative HCV RNA test result at screening are eligible.\n\n    19\\. Pregnant or breastfeeding women 20. Any condition requiring treatment with prohibited or restricted concomitant medication or therapy as described in Section 6.2.2",{"count":106,"type":21},172,[108],"PHASE3","This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.",[111],"Esophageal Cancer","2026-05-29",{"date":114,"type":36},"2026-06-02",{"date":116,"type":21},"2026-05-06",{"date":118,"type":21},"2034-05-30",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":85,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100631046","phase-2-lenvatinib-or-regorafenib-for-advanced-hepatocellular-carcinoma-after-immunotherapy-revive-100631046","NCT07495579","Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","A Multicenter Phase 2 Study of Lenvatinib or Regorafenib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Who Progressed After First-Line Immunotherapy-Based Combination Therapy (REVIVE)","REVIVE","Inclusion Criteria:\n\n* Age 19 years or older\n* Diagnosis of hepatocellular carcinoma according to the American Association for the Study of Liver Diseases (AASLD) guidelines\n* Unresectable or metastatic hepatocellular carcinoma not amenable to curative treatments such as surgical resection, liver transplantation, or local ablation\n* Prior first-line systemic treatment with an immune checkpoint inhibitor-based combination regimen, defined as dual immune checkpoint inhibitor therapy (e.g., nivolumab plus ipilimumab or durvalumab plus tremelimumab) for the REVIVE-1 cohort, and immune checkpoint inhibitor-based combination therapy (e.g., atezolizumab plus bevacizumab, durvalumab plus tremelimumab, nivolumab plus ipilimumab, camrelizumab plus rivoceranib, or similar regimens) for the REVIVE-2 cohort; prior participation in clinical trials using these regimens is allowed\n* Radiologic disease progression after at least 2 cycles of first-line treatment\n* At least one measurable lesion according to RECIST v1.1\n* Recovery from toxicities related to prior therapy to grade 1 or lower, except for clinically stable or non-clinically significant toxicities\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy of at least 12 weeks\n* Absolute neutrophil count ≥ 1.0 × 10⁹\u002FL\n* Platelet count ≥ 75 × 10⁹\u002FL for REVIVE-1 or ≥ 50 × 10⁹\u002FL for REVIVE-2\n* Hemoglobin ≥ 9 g\u002FdL\n* Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 40 mL\u002Fmin\n* Proteinuria \\\u003C3 g in 24-hour urine collection or urine protein-to-creatinine ratio \\\u003C3 mg\u002Fmg\n* Child-Pugh A (score 5-6) for REVIVE-1 cohort or Child-Pugh B (score 7-8) for REVIVE-2 cohort\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)\n* Patients with chronic hepatitis B infection receiving appropriate antiviral therapy if HBV DNA positive\n* QTcF ≤ 480 ms on electrocardiogram obtained within 21 days prior to enrollment\n* Ability to understand and willingness to sign written informed consent\n* Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 4 months after the last dose\n\nExclusion Criteria:\n\n* Known fibrolamellar hepatocellular carcinoma or mixed hepatocellular-cholangiocarcinoma\n* Prior treatment with lenvatinib or regorafenib\n* Receipt of two or more prior systemic treatment regimens for advanced hepatocellular carcinoma\n* Known brain metastases or epidural disease unless adequately treated and clinically stable for at least 3 months\n* Congestive heart failure greater than New York Heart Association class II\n* Unstable angina, myocardial infarction, or stroke within 6 months\n* Clinically significant cardiac arrhythmia requiring treatment\n* Uncontrolled hypertension despite optimal medical therapy (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mmHg)\n* Active bleeding disorders or high risk of severe bleeding\n* Tumor invasion of major blood vessels with high risk of bleeding\n* Gastrointestinal conditions with high risk of perforation or fistula, including active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis, or recent gastrointestinal perforation\n* Major surgery within 2 months before enrollment or incomplete recovery from surgery\n* Moderate to severe ascites\n* Known hypersensitivity to study drugs or their components\n* Pregnancy or breastfeeding\n* Diagnosis of another active malignancy requiring treatment within the past 2 years, except for adequately treated low-risk cancers\n* Uncorrected electrolyte abnormalities\n* Any medical condition that, in the investigator's judgment, would make the participant unsuitable for the study",{"count":129,"type":21},146,[131],"PHASE2","The goal of this clinical trial is to learn if lenvatinib or regorafenib can help treat people with advanced liver cancer (hepatocellular carcinoma, HCC) that cannot be removed with surgery after first treatment with immunotherapy-based drug combinations. It will also look at the safety of these treatments.\n\nThe main questions this study aims to answer are:\n\n* How long lenvatinib can delay cancer growth in people with good liver function (Child-Pugh)A after dual immunotherapy\n* How long people with reduced liver function (Child-Pugh B7-B8) live after treatment with lenvatinib or regorafenib after first-line immunotherapy-based combination treatment\n* What side effects people experience during treatment\n* How many people have their tumors shrink or disappear\n\nThe study has two parts:\n\nIn REVIVE-1, participants with Child-Pugh A liver function will receive lenvatinib.\n\nIn REVIVE-2, participants with Child-Pugh B7 to B8 liver function will receive either lenvatinib or regorafenib.\n\nParticipants will:\n\n* take lenvatinib or regorafenib by mouth\n* visit the clinic regularly for physical exams, blood and urine tests, and safety checks\n* have computed tomography (CT) scans every 8 weeks to check their cancer\n* be followed during and after treatment to assess outcomes and side effects",[134],"Hepatocellular Carcinoma (HCC)",[136,137,138,139,140,141],"Hepatocellular Carcinoma","Lenvatinib","Regorafenib","Second-line Therapy","Dual Immune Checkpoint Inhibitor","Child-Pugh B","2026-05-22",{"date":144,"type":36},"2026-05-27",{"date":146,"type":21},"2026-04",{"date":148,"type":21},"2028-12",{"name":42,"class":43},1,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":85,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":150},"100382849","utilization-of-microbiome-as-biomarkers-and-therapeutics-in-immuno-oncology-100382849","NCT04264975","Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology","Part 1: development of microbiome biomarkers\n\n\\\u003CInclusion Criteria:\\> 1.Patients with pathologically confirmed solid cancer who are being treated with immunotherapy or are going to receive immunotherapy\n\n1. Age ≥ 19 years old\n2. Eastern Cooperative Oncology Group performance status 0-2\n3. Measurable or evaluable lesion(s) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n\n\\\u003CExclusion Criteria\\>\n\n1. A history of other cancers requiring treatment within the recent 3 years (excepting treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, breast, or stomach)\n2. A history of active primary immunodeficiency\n3. Active infection including tuberculosis or Human Immunodeficiency Virus (HIV)\n4. Autoimmune disease (excepting type 1 diabetes mellitus, hypothyroidism requiring hormone replacement therapy only, skin disease not requiring systemic therapy (such as vitiligo, psoriasis or alopecia)\n5. Patients who are receiving immunosuppressive medications (excepting topical steroids, systemic steroid ≤10 mg\u002Fday prednisone or equivalents, or a brief course of steroids for prophylaxis (e.g., hypersensitivity reaction)\n\n   \\--------------------------------------------------------------------------------------------\n\npart 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for solid cancers\n\n\\\u003CInclusion Criteria for donors\\>\n\n1. Patients who have partial or complete response to immunotherapy at the time of stool donation\n2. No history of exposure to HIV or hepatitis virus within the previous 12 months\n3. No history of international travel within previous 6 months to areas of high risk of travelers' diarrhea\n4. No current communicable disease\n5. No household members with active gastrointestinal infection\n6. No history of inflammatory bowel disease\n7. No recent intake of potential allergenic foods that are known to cause hypersensitivity in a recipient (such as peanut)\n\n\\\u003CInclusion criteria for recipients\\>\n\n1. Patients without contraindications for colonoscopy such as suspected bowel perforation, acute diverticulitis, or fulminant colitis\n2. Patients who have disease progression to immunotherapy as one of the following two patterns:\n\n2-1) Patients who have disease progression due to primary resistance to immunotherapy\n\n2-2) Patients who have disease progression following disease stabilization due to secondary resistance to immunotherapy",{"count":5,"type":21},[159],"NA","This is an open label, single-center, non-randomized clinical trial on utilization of microbiome as biomarkers and therapeutics in immuno-oncology.\n\nThis research consists of two parts:\n\npart 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for advanced solid tumor",[162],"Solid Carcinoma",[164,165,166,167,168],"immuno-oncology","immunotherapy","biomarker","fecal microbiota transplantation (FMT)","microbiome","2026-05-20",{"date":142,"type":36},{"date":172,"type":36},"2018-06-04",{"date":40,"type":21},{"name":42,"class":43},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":186,"studyType":22,"phases":4,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":150},"100633723","blood-viscosity-and-outcomes-after-elective-craniotomy-100633723","NCT07530393","Blood Viscosity and Outcomes After Elective Craniotomy","Association of Intraoperative Blood Viscosity With Cerebral Oxygenation and Postoperative Composite Complications in Adults Undergoing Elective Intracranial Craniotomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Patients scheduled to undergo elective intracranial craniotomy\n* Patients requiring intraoperative arterial catheterization and routine arterial blood gas analysis\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Patients in whom participation or follow-up is considered difficult by the investigator\n* Patients unable to provide informed consent","18 Years","80 Years",{"count":185,"type":21},1000,"30 Days","This prospective observational study aims to evaluate the association between intraoperative blood viscosity and postoperative clinical outcomes in adult patients undergoing elective intracranial craniotomy.\n\nBlood viscosity is an important determinant of microcirculatory flow and cerebral perfusion, but its role in perioperative outcomes remains unclear. In this study, intraoperative blood viscosity and related hematologic parameters will be measured, and their relationships with cerebral oxygenation and postoperative complications will be analyzed.\n\nThe study will enroll adult patients undergoing elective intracranial surgery at a single tertiary center. The findings of this study may improve understanding of perioperative hemodynamic and hemorheological factors and help identify potential risk markers for adverse postoperative outcomes.",[189,190],"Postoperative Complications","Intracranial Surgery",[192,193,194,195,196,197],"blood viscosity","intracranial craniotomy","neurosurgery","cerebral oxygenation","postoperative complications","hemodynamics","2026-04-07",{"date":200,"type":36},"2026-04-15",{"date":202,"type":21},"2026-05-01",{"date":204,"type":21},"2030-03-31",{"name":42,"class":43},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":85,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":150},"100600370","phase-1-lenvatinib-after-progression-on-imatinib-sunitinib-and-regorafenib-for-gist-patients-100600370","NCT07096609","Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients","A Single-center, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Lenvatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Who Have Failed Treatment With Imatinib, Sunitinib, and Regorafenib","LONGIST","Inclusion Criteria:\n\n1. Age ≥ 20 years at the time of providing written informed consent.\n2. Histologically confirmed metastatic and\u002For advanced (unresectable or recurrent) GIST with positivity for CD117(+), DOG-1(+), or harboring mutations in the KIT or PDGFRα genes.\n3. Documented failure of prior treatment with imatinib, sunitinib, and regorafenib due to disease progression and\u002For intolerance.\n\n   * Note: There is no limitation on the number of prior therapies. Prior use of other tyrosine kinase inhibitors (TKIs) or chemotherapy in combination with imatinib, sunitinib, or regorafenib is permitted.\n   * Disease progression is defined as:\n\n     1. Increase in tumor size by ≥ 20% per mRECIST version 1.1\n     2. Emergence of unequivocal new lesions (excluding newly developed small cystic liver lesions within 6 months after initiation of TKI treatment)\n     3. Appearance of new solid nodules within cystic masses\n     4. Increase in the size of existing solid nodules within cystic masses (\\>20%)\n   * Intolerance to prior TKIs is defined as:\n\n     1. Drug compliance \\\u003C75% due to ≥ Grade 2 non-hematologic toxicity, despite dose reduction to one level below the standard dose (i.e., imatinib 300 mg\u002Fday; sunitinib 37.5 mg\u002Fday on a 4-week on\u002F2-week off schedule or 25 mg\u002Fday on a continuous schedule; regorafenib 120 mg\u002Fday)\n     2. Despite the same dose reduction as above, the occurrence of febrile neutropenia, Grade 4 neutropenia lasting more than 6 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3-4 or persistent ≥ Grade 2 non-hematologic toxicity deemed intolerable\n4. ECOG performance status of 0-2.\n5. All toxicities from previous treatments must have recovered to Grade 0 or 1 as per NCI-CTCAE version 5.0.\n6. At least one measurable lesion as defined by mRECIST version 1.1.\n7. Adequate bone marrow, liver, renal, and other organ function:\n\n   * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³\n   * Platelets ≥ 100,000\u002Fmm³\n   * Hemoglobin ≥ 8.0 g\u002FdL\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n   * AST\u002FALT ≤ 2.5 × ULN (or ≤ 5 × ULN in case of liver metastases)\n   * Serum creatinine ≤ 1.5 × ULN\n8. Life expectancy ≥ 12 weeks\n9. A washout period equivalent to at least 4 times the half-life of previous TKI or chemotherapeutic agents is required(Imatinib and regorafenib: ≥ 1 week; Sunitinib: ≥ 2 weeks)\n10. Signed written informed consent\n\nExclusion Criteria:\n\n1. Women of childbearing potential who are pregnant or breastfeeding\n2. Women or men unwilling to use effective contraception during the study treatment period and for 6 months after the last dose of the investigational drug\n3. All participants (both men and women) must use barrier contraception during the treatment period and for at least 1 month after the final dose\n4. Women of childbearing potential are defined as sexually mature females who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., had menstruation within the past 12 months)\n5. History of any of the following within 6 months prior to enrollment: myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass surgery, congestive heart failure classified as NYHA Class III or IV, stroke or transient ischemic attack (TIA), or clinically significant arrhythmias requiring treatment\n6. Uncontrolled active infection\n7. Diabetes mellitus with clinically significant signs of peripheral vascular disease\n8. Acute or chronic liver disease, or any chronic hepatic disorder (patients with stable chronic hepatitis B are eligible)\n9. Uncontrolled gastrointestinal toxicities greater than Grade 2 according to NCI-CTCAE (e.g., nausea, diarrhea, vomiting)\n10. Any severe acute or chronic medical or psychiatric condition, or clinically significant abnormal laboratory finding, that may increase the risk associated with study participation or investigational drug administration, or interfere with the interpretation of study results, as determined by the investigator\n11. History of life-threatening bleeding or any Grade 3 or 4 bleeding event requiring transfusion, endoscopic intervention, or surgical procedure within 3 months prior to initiation of study drug\n12. Treatment with clinically significant systemic anticoagulant or antithrombotic agents within 7 days prior to consent that, in the opinion of the investigator, may put the patient at risk. Use of aspirin is permitted up to a maximum dose of 325 mg\u002Fday\n13. Uncontrolled hypertension (blood pressure ≥ 140\u002F90 mmHg) that is not adequately managed with medication, or change in antihypertensive regimen within 7 days prior to consent; such patients may be at increased risk during VEGF inhibitor therapy\n14. Major surgery, significant trauma (e.g., bone fracture), or non-healed wounds within 3 weeks prior to consent (procedures such as catheter insertion are not considered major)\n15. History of other significant cardiovascular or vascular conditions within 6 months prior to consent that, in the opinion of the investigator, may place the patient at risk during VEGF inhibitor therapy, including but not limited to hypertensive crisis, hypertensive encephalopathy, stroke, transient ischemic attack (TIA), or clinically significant peripheral vascular disease\n16. Clinically significant glomerulonephritis, biopsy-proven tubulointerstitial nephritis, crystal nephropathy, or other history of renal failure\n17. Known diagnosis of HIV infection (HIV testing is not mandatory)\n18. History of another primary malignancy that has recently become clinically significant or currently requires active intervention\n19. Evidence of brain metastasis on radiological imaging (e.g., CT or MRI) in patients presenting with symptoms suggestive of central nervous system involvement\n20. History of alcohol or substance abuse disorder","20 Years",{"count":216,"type":21},48,[218,131],"PHASE1","The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.",[221],"GIST",[221,137],"2026-04-02",{"date":225,"type":36},"2026-04-03",{"date":227,"type":36},"2025-10-29",{"date":229,"type":21},"2027-12-31",{"name":42,"class":43},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":85,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":150},"100541168","phase-2-gist-oral-paclitaxelliporaxel-100541168","NCT06326346","GIST Oral Paclitaxel(Liporaxel)","A Phase II Study of Oral Paclitaxel (Liporaxel) in GIST Patients With a Low P-glycoprotein Expression After Failure With Imatinib, Sunitinib and Regorafenib","Inclusion Criteria:\n\n1. Age 20 years or older, at the time of acquisition of informed consent\n2. Histologically confirmed metastatic and\u002For advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene\n3. Failed (progressed and\u002For intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.\n4. Adequate tissue obtained after treatment failure to imatinib, sunitinib, and regorafenib for P-glycoprotein immunohistochemistry (IHC) analysis, and showed P-glycoprotein expression of less than 6. (For patients with PDGFRα D842V mutation or other subtypes with poor response to tyrosine kinase inhibitors, tumor tissue obtained at any period can be used.)\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0\\~2\n6. Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0\n7. At least one measurable lesion as defined by RECIST version 1.1.\n8. Adequate bone marrow, hepatic, renal, and other organ functions\n\n   * Neutrophil \\>1,500\u002Fmm3\n   * Platelet \\> 100,000\u002Fmm3\n   * Hemoglobin \\>8.0 g\u002FdL\n   * Total bilirubin \\\u003C 1.5 x upper limit of normal (ULN)\n   * AST\u002FALT \\\u003C 2.5 x ULN\n   * Creatinine \\\u003C1.5 x ULN\n9. Life expectancy \\> 12 weeks\n10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imatinib and regorafenib need 1 week and sunitinib need 2 weeks.)\n11. Provision of a signed written informed consent\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breast feeding\n2. Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration.\n3. If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary\u002Fperipheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia.\n4. Uncontrolled infection\n5. Diabetes mellitus with clinically significant peripheral artery disease\n6. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible)\n7. Uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2\n8. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator\n9. The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleeding event. (required transfusion or endoscopic or surgical intervention)\n10. Patient who underwent major surgery or is under recovery from surgery within 28 days from the study treatment\n11. Known diagnosis of HIV infection (HIV testing is not mandatory).\n12. History of another primary malignancy that is currently clinically significant or currently requires active intervention.\n13. Patients with clinically suspected brain metastasis symptom, brain metastases as assessed by radiologic imaging.\n14. Alcohol or substance abuse disorder.\n15. Known severe hypersensitivity to paclitaxel\n16. Received paclitaxel-based treatment for GIST",{"count":239,"type":21},28,[131],"The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.",[243],"Gastrointestinal Stromal Tumors",{"date":198,"type":36},{"date":246,"type":36},"2024-11-20",{"date":248,"type":21},"2027-03-31",{"name":42,"class":43},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":85,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":150},"100508858","phase-2-rivoceranib-plus-paclitaxel-in-patients-with-gastrointestinal-stromal-tumor-100508858","NCT05905887","Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib","Inclusion Criteria:\n\n* Age 20 years or older, at the time of acquisition of informed consent\n* Histologically confirmed metastatic and\u002For advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene\n* P-glycoprotin IHC score \\> 3 (Tumor tissue with disease progression after regorafenib treatment)\n* Failed (progressed and\u002For intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 \\~ 2\n* Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0\n* At least one measurable lesion as defined by RECIST version 1.1.\n* Adequate bone marrow, hepatic, renal, and other organ functions Neutrophil \\>1,500\u002Fmm3 Platelet \\> 100,000\u002Fmm3 Hemoglobin \\>8.0 g\u002FdL Total bilirubin \\\u003C 1.5 x upper limit of normal (ULN) AST\u002FALT \\\u003C 2.5 x ULN Creatinine \\\u003C1.5 x ULN\n* Life expectancy \\> 12 weeks\n* Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imitinib and regorafenib need 1 week and sunitinib need 2 weeks.)\n* Provision of a signed written informed consent\n\nExclusion Criteria:\n\n* Women of child-bearing potential who are pregnant or breast feeding\n* Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration.\n* If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary\u002Fperipheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia.\n* Uncontrolled infection\n* Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible)\n* Uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2\n* Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator\n* The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleedig event. (required transfusion or endoscopic or surgical intervention)\n* Currently clinically significant (within 7 days prior to screening) treatment of anticoagulants or other thrombolytic agents. A maximum dose of 325 mg\u002Fday of aspirin is allowed\n* History of uncontrolled hypertension (blood pressure ≥140\u002F90 mmHg and change in antihypertensive medication within 7 days prior to screening) that is not well managed by medication and the risk of which may be precipitated by a VEGF inhibitor therapy.\n* History of clinically serious opearation, bone fracture or non-healing wounds within the last 3 weeks prior to screening\n* History of other significant cardiovascular diseases or vascular diseases, within the last 6 months prior to screening (e.g., hypertensive crisis, and hypertensive encephalopathy or transient ischemic attack or significant peripheral vascular diseases\\] that, in the investigator's opinion, may pose a risk to the patient on VEGFR inhibitor therapy.\n* History of clinically significant glomerulonephritis, biopsy-proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies\n* Known diagnosis of HIV infection (HIV testing is not mandatory).\n* History of another primary malignancy that is currently clinically significant or currently requires active intervention.\n* Patients with clinically suspected brain metastasis symptom, brain metastases as assessed by radiologic imaging\n* Alcohol or substance abuse disorder.\n* Known hypersensitivity to rivoceranib or any component of its formulation or history of severe hypersensitivity to including Cremophor R EL(polyoxyethylated castor oil) drug\n* Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19\n* Active bacterial infections",{"count":216,"type":21},[131],"The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.",[243],{"date":198,"type":36},{"date":263,"type":36},"2023-09-06",{"date":229,"type":21},{"name":42,"class":43},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":221,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":85,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":150},"100490093","phase-2-the-efficacy-and-safety-of-temozolomide-in-sdh-deficient-gist-100490093","NCT05661643","The Efficacy and Safety of Temozolomide in SDH-deficient GIST","A Phase 2 Study to Evaluate the Efficacy and Safety of Temozolomide in Advanced Gastrointestinal Stromal Tumor Patients With SDH Deficiency","Inclusion Criteria:\n\n1. Age 20 years or older, at the time of acquisition of informed consent\n2. Histologically confirmed GIST with CD117(+), DOG-1(+)\n3. Wild type GIST without KIT or PDGFRα gene mutations determined by Sanger sequencing and panel sequencing\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 \\~ 2\n5. Resolution of all adverse events with prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0\n6. At least one measurable lesion by RECIST version 1.1.\n7. Adequate bone marrow, hepatic, renal, and other organ functions, before adjuvant imatinib treatment\n\n   * Neutrophil \\>1,500\u002Fmm3\n   * Platelet \\> 100,000\u002Fmm3\n   * Hemoglobin \\>8.0 g\u002FdL\n   * Total bilirubin \\\u003C 1.5 x upper limit of normal (ULN)\n   * AST\u002FALT \\\u003C 2.5 x ULN\n   * Creatinine \\\u003C1.5 x ULN\n8. Life expectancy ≥12 weeks\n9. Disease progression or discontinuation of treatment due to intolerable toxicity at least with palliative 1st line imatinib .\n10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imitinib and regorafenib need 1 week and sunitinib need 2 weeks.)\n11. Provision of a signed written informed consent\n\nExclusion Criteria:\n\n1. Confirmed GIST with KIT or PDGFRα gene mutations determined by Sanger sequencing and panel sequencing\n2. Women of child-bearing potential who are pregnant or breast feeding\n3. Women or men who are not willing to use effective contraception entering the study period or until at least 6 months after the last study drug administration\n4. If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary\u002Fperipheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia\n5. Uncontrolled infection\n6. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible\n7. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator\n8. Known diagnosis of HIV infection (HIV testing is not mandatory).\n9. History of another primary malignancy that is currently clinically significant or currently requires active intervention.\n10. Alcohol or substance abuse disorder\n11. The patients with NTRK fusion\n\n5\\)",{"count":274,"type":21},29,[131],"The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.",[243],{"date":198,"type":36},{"date":280,"type":36},"2023-06-28",{"date":229,"type":21},{"name":42,"class":43},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":85,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":150},"100456636","phase-3-efficacy-and-safety-of-ferric-carboxymaltose-in-patients-with-advanced-gastric-cancereffect-agc-100456636","NCT05226169","Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)","Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 19 years at the time of study registration\n2. Eastern Cooperative Oncology Group performance status ≤ 2\n3. Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma\n4. Locally advanced unresectable or metastatic disease\n5. Patients who have not been treated with palliative systemic antitumor agents for advanced or recurrent gastric or GEJ adenocarcinoma\n6. Patients scheduled to receive palliative first-line fluoropyrimidine and platinum-based systemic therapy including targeted therapy or immunotherapy\n7. Life expectancy ≥24 weeks\n8. IDA\n\n   1. Hb 8 to \\\u003C11 g\u002FdL\n   2. Absolute ID (serum ferritin \\\u003C 100 ng\u002FmL) OR functional ID (TSAT\\* \\\u003C 50% and serum ferritin 100-500 ng\u002FmL)\n\n      * TSAT = (serum iron level x 100)\u002F total iron-binding capacity (TIBC)\n\nExclusion Criteria:\n\n1. Body weight \\\u003C 35 kg\n2. Immediate need for transfusion or Hb \\\u003C 8 g\u002FdL\n3. Possible functional ID or No ID (serum ferritin \\> 500 ng\u002FmL OR TSAT ≥ 50%)\n4. Anemia attributable to factors other than cancer or chemotherapy (e.g., vitamin B12 and\u002For serum folate deficiency; hemolysis; or myelodysplastic syndromes)\n5. Ongoing bleeding or overt gross active bleeding (e.g., hematemesis, melena, or hematochezia)\n6. Neoplastic bone marrow infiltration\n7. History of ESA, IV or oral iron therapy, and\u002For RBC transfusion 4 weeks prior to randomization\n8. Iron overload or disturbances in utilization of iron (e.g., personal or family history of hemochromatosis and hemosiderosis)\n9. Known hypersensitivity to any of the required study products or known serious hypersensitivity to other parenteral iron products\n10. Known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergies, and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis)\n11. Decreased renal function including renal dialysis (previous, current or planned within the next 6 months,) or serum creatinine levels ≥ 2.0 mg\u002FdL, or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n12. Chronic liver disease (including active hepatitis) and\u002For aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 times the upper limit of the normal range\n13. Active acute or chronic infections (assessed by clinical judgment)\n14. Other significant medical condition(s) in the opinion of the investigator with an anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject or may interfere with study assessments, outcomes (e.g., uncontrolled hypertension, active cardiac disease, thromboembolic disease, or uncontrolled diabetes mellitus, neurological or psychiatric disorders)\n15. Pregnancy (e.g., positive human chorionic gonadotropin test) or breast-feeding. If the subject is of childbearing potential and does, not use adequate contraceptive precautions. The subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.",{"count":291,"type":21},330,[108],"The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will also evaluate the effect of IV FCM on the treatment outcomes of palliative chemotherapy in patients with gastric cancer receiving fluoropyrimidine and platinum-based regimen in the same 1st-line palliative setting.",[295],"Advanced Gastric Carcinoma",{"date":225,"type":36},{"date":298,"type":36},"2022-04-29",{"date":300,"type":21},"2026-11-30",{"name":42,"class":43},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":85,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":150},"100453458","phase-2-a-phase-2-study-of-neoadjuvant-docetaxel-oxaliplatin-s-1-in-patients-with-unresectable-locally-advanced-or-distant-metastasis-limited-to-lymph-node-gastric-cancer-100453458","NCT05184803","A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer","Inclusion Criteria:\n\n1. Histologically or cytologically proven metastatic gastric adenocarcinoma patients\n2. As a patient who has been proven by CT to have invasion of surrounding organs (T4) according to the 8th edition of the American Joint Commission (AJCC) or confined to remote lymph nodes, the criteria for lymph node invasion are 8 mm or more in single diameter and central necrosis (rounder), (Refer to Appendix B)\n3. Over 18 years old.\n4. Patients with a life expectancy of at least 3 months.\n5. Patients with 0 or 1 ECOG performance status\n6. As defined in the relevant items below, those who have confirmed appropriate normal organ and bone marrow function:\n\n   * Haemoglobin 9 9.0 g\u002FdL.\n   * Absolute neutrophil count (ANC) \\> 1.5 x 103\u002FmCL (\\> 1,500 per mm3)\n   * Platelet count 100 100 x 109\u002FL\n   * Serum bilirubin 1.5 1.5 x Test Laboratory Upper Limit of Normal (ULN).\n   * AST(SGOT)\u002FALT(SGPT) 2.5 2.5x ULN of test institution.\n   * Measured creatinine clearance (CL) \\> 40 mL\u002Fmin or Cockcroft-Gault formula (Cockcroft and Gault 1976) calculated by or according to 24-hour urine samples for determining creatinine cleaning rates.\n\n     * Male creatinine CL (mL\u002Fmin) = Weight (kg)x (140-age) \u002F 72x Serum creatinine (mg\u002FdL)\n     * Women's creatinine CL (mL\u002Fmin) = Weight (kg)x (140-age) \u002F 72 x Serum creatinine (mg\u002FdL) x 0.85\n7. A patient who has never had chemotherapy before.\n8. Patients who have not previously had radiation therapy experience\n9. Physical, family, social, and geographic conditions for the follow-up of patient conditions required for this study should be free of obstacles in this study.\n10. Evidence of menopause or negative findings of urine or blood pregnancy response should be confirmed in premenopausal women. Women who are premenstrual for more than 12 months without any other medical cause are considered menopause. In addition, if bilateral ovarian resection, bilateral ovariectomy, and hysterectomy are performed, menopause is considered.\n11. Subjects who can provide signed consent, such as compliance with the requirements and taboos specified in the test subject's consent (ICF) and this plan. Written consent must be obtained from the patient and the patient's legal representative prior to implementing the plan-related procedures, including screening evaluation.\n\nExclusion Criteria:\n\n1. When pregnant women, lactating women, or pregnant women do not use appropriate contraception methods.\n2. Cancer other than adenocarcinoma.\n3. Patients with distant metastasis other than lymph nodes or confirmed ascites on abdominal CT before surgery.\n4. History of other carcinomas or presence of pathogenic cancer (excluding non-melanoma skin cancer or cervical epithelial cancer)\n5. Central nervous system metastasis.\n6. Clinically significant intestinal obstruction or gastrointestinal bleeding.\n7. A patient with a history of organ transplantation.\n8. Active infections such as tuberculosis, hepatitis B, hepatitis C, or HIV identified by TB tests according to medical history, physical examination, radiological findings, and regional standards.\n\n   * Tuberculosis: Tuberculosis confirmed by medical history, physical examination, or radiologically active tuberculosis, and tuberculosis tests according to regional standards (excluding active TB, old TB is acceptable)\n   * Hepatitis B: If HBsAg is negative, register, and if HBsAg is positive, HBV DNA test is performed.\n\n     * HBV DNA 500 500iu\u002Fml (or 2500 copies\u002Fml): Excluded\n     * HBV DNA ▶500iu\u002Fml (or 2500 copies\u002Fml): Allow\n   * Hepatitis C: If HCV Ab is negative, register, and if HCV Ab is positive, HCV RNA test is performed.\n\n     * If HCV RNA is positive, I'll exclude it.\n     * If it's HCV RNA's voice, it's allowed.\n   * HIV: HIV Ag\u002FAb : excluding reactive faces, HIV Ag\u002FAb : non-reactive faces registration\n9. Average QTcF (average QT interval for heart rate correction using fridericia formula) \\> 470 ms when calculated with three ECG tests (within 15 minutes at 2-5 minute intervals).\n\n   If -1 test is performed and QTcF \\> 470 ms, 2 additional tests are performed to determine the average QTcF value.\n\n   -If QTcF 4 470 ms after one test, no additional test is performed.\n10. Other serious diseases or medical conditions.\n\n    * Uncurable unstable heart disease, myocardial infarction within 6 months before the start of the study.\n    * A history of neurological or psychiatric diseases including dementia or seizures.\n    * Active, non-regulatory infection.\n    * Clinically serious diarrhea.\n    * Severe high calcium conditions above 12 mg\u002FdL, which are not controlled by phonates.\n    * Other serious medical conditions that may affect participation in this study.\n    * Active random intravascular coagulation.\n11. Patients who other researchers find inappropriate.\n12. In the case of recent corticosteroids (or corresponding) treatment, except for acute hypersensitivity response therapy or low-dose (\\\u003C20 mg methylprednisolone or corresponding) chronic treatment (started 6 months before the start of the study) as preventive therapy,\n13. In addition to the test drug, administration of other clinical research drugs within 4 weeks or in combination.\n14. Combination chemotherapy, hormone therapy, or immunotherapy.",{"count":309,"type":21},63,[131],"Gastric cancer is the fifth most common carcinoma in the world, and cancer-related deaths rank third. It is one of the main causes of death from cancer in Korea. The cure method for gastric cancer is radical resection, but in most patients, radical resection is impossible due to local infiltration or peripheral organ or distant metastasis. Many assisted chemotherapy has been studied to improve survival rate, and in East Asia, assisted chemotherapy after complete D2 resection is the standard treatment. In the West, on the other hand, preoperative chemotherapy and postoperative assisted chemotherapy are currently standard treatments. However, due to the limited effect of adjuvant chemotherapy, it has been reported that better clinical course can be improved by increasing anticancer intensity.\n\nIn this context, a large number of prior chemotherapy have been attempted, and prior chemotherapy has several potential effects as follows. (1) Improvement of R0 resection rate due to reduced primary cancer size, (2) early treatment for micro metastasis, (3) evaluation of treatment response rate in patients with measurable lesions, and (4) unnecessary laparotomy can be avoided in patients with biologically aggressive diseases.\n\nBased on the efficacy of chemotherapy in the combination of docetaxel, fluoropyrimidine, and platinum in metastatic gastric cancer, the investigators conducted a preceding auxiliary anti-cancer clinical trial of docetaxel, capecitabine and cisplatin in advanced gastric cancer patients who could not be completely resected by surgery. DXP was performed 4-6 cycles before surgery with the recommended dose in phase 1-2. In a total of 49 patients, R0 resection was performed in 31 (63%), and among patients, R0 resection was improved in cases where resection was not possible due to local infiltration (71%) and in cases where para-aortic node metastasis was performed (73%).\n\nWe have reported that docetaxel, oxaliplatin, and S-1 chemotherapy (DOS) as preoperative adjuvant therapy can be safely administered in combination with D2 gastrectomy and postoperative adjuvant therapy S-1 in potentially resectable local progressive gastric cancer patients. R0 resection was achieved in 97.6% of patients, and pathological complete remission was observed in 19.5%. Based on this, a phase 3 PRODIGY study was performed to evaluate the benefit of S-1 (CSC group) as a preoperative prior chemotherapy compared to S-1 (SC group) as a postoperative adjuvant therapy in gastric cancer of cT2\u002F3N+ or cT4Nany stage, and 0.75% of the CSC group was administered HR. In the patient group undergoing surgery, the R0 resection rate was 95% in the CSC group and 84% in the SC group. In the CSC group, the pathological complete remission rate was 10.4%.\n\nBased on these results, a clinical trial of DOS as a preoperative chemotherapy was planned for progressive gastric cancer that could not be resected due to local progression or metastasis limited to remote lymph nodes.\n\nPrimary goal: Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.\n\nSecondary objective: safety evaluation, overall survival period, progression-free survival period, pathological complete remission rate, and investigation of biological markers.",[313],"Stomach Neoplasm",[315,316,317],"Neo-adjuvant\u002FAdjuvant","distant metastasis limited to lymph node gastric cancer","unresectable locally advanced gastric cancer",{"date":198,"type":36},{"date":320,"type":36},"2022-03-23",{"date":229,"type":21},{"name":42,"class":43},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":150},"100500836","a-study-to-evaluate-coronary-atherosclerosis-in-patients-with-diabetes-mellitus-100500836","NCT05801432","A Study to Evaluate Coronary Atherosclerosis in Patients With Diabetes Mellitus","Diabetes Follow-up Study for REduction of cardiovAscular outcoMes: a Coronary Computed Tomographic Angiography Cohort Study","DREAM-CCTA","Inclusion Criteria:\n\n* Age 19 years or older\n* Asymptomatic patients with type 2 DM who had undergone initial CCTA evaluation at the Diabetes Center of the Asan Medical Center between February 2008 and June 2012\n* Willing and able to provide informed written consent\n\nExclusion Criteria:\n\n* Blood test results that the Creatinine level exceeds 1.5 mg\u002FdL\n* A person with a history of anaphylaxis or allergic shock associated with a contrast medium\n* Pregnant women\n* Unable to undergo follow-up CCTA\n* Uninterpretable CCTA",{"count":332,"type":21},511,"The purpose of this study is to evaluate the natural history of coronary atherosclerosis development and progression over time by CCTA and to identify risk factors attributable to the development of coronary atherosclerosis in a Korean DM population.",[335],"Diabetes Mellitus","2026-03-26",{"date":338,"type":36},"2026-03-30",{"date":340,"type":36},"2021-08-24",{"date":342,"type":21},"2026-12-31",{"name":42,"class":43},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":85,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100574321","phase-4-the-effect-and-safety-of-combined-anti-platelet-treatment-in-acute-ischemic-stroke-due-to-large-artery-atherosclerosis-100574321","NCT06757764","The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial","CHANGE","Inclusion Criteria:\n\n1. Age of 20 years or older\n2. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography.\n3. Informed consent obtained within 72h from stroke onset\n4. Acquisition of written informed consent prior to study entry\n\nExclusion Criteria:\n\n1. Large infarction unable to start antiplatelet treatment\n2. Combined with acute intracranial haemorrhage\n3. With initial haemorrhagic transformation\n4. Previous mRS higher than 2\n5. Indicated for anticoagulation\n6. Contraindication for aspirin, clopidogrel or cilostazol\n7. Requirement of long term NSAID\n8. Pre-planned for surgery\n9. Unable to withdraw consent\n10. Unavailable to participate based on judgement of the investigator\n11. Participants of reproductive potential (PORP)\u002F Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.",{"count":353,"type":21},2340,[87],"Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.",[357,358],"Cerebral Infarction","Stenosis Artery","2026-03-25",{"date":361,"type":36},"2026-03-27",{"date":363,"type":36},"2025-07-10",{"date":365,"type":21},"2028-03-31",{"name":42,"class":43},24,{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":85,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":150},"100630298","phase-3-influenza-vaccination-strategy-for-patients-with-hematologic-malignancy-100630298","NCT07485855","Influenza Vaccination Strategy for Patients With Hematologic Malignancy","Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies","(HEM-FLU)","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Confirmed diagnosis of hematologic malignancy, including:\n\nnon-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders\n\nExclusion Criteria:\n\n* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)\n* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures\n* Known hypersensitivity to influenza vaccine components\n* Influenza vaccination within the preceding 6 months\n* Any other condition deemed clinically inappropriate for study participation at investigator discretion",{"count":5,"type":21},[108],"This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population",[380,381,382],"Hematologic Neoplasms","Influenza","Immunogenicity","2026-03-20",{"date":385,"type":36},"2026-03-24",{"date":387,"type":36},"2025-12-04",{"date":389,"type":21},"2028-04-30",{"name":42,"class":43},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":85,"phases":399,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":150},"100630547","feasibility-of-a-digital-rehabilitation-platform-in-patients-after-icu-discharge-100630547","NCT07489092","Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge","Inclusion Criteria:\n\n* Age 19 years or older.\n* Admission to the intensive care unit (ICU) for more than 48 hours.\n* Hospitalization at Asan Medical Center or Seoul National University Bundang Hospital.\n* Discharge from the ICU at the time of enrollment.\n* Ownership of a smartphone and ability to operate a digital rehabilitation platform.\n* Ability to understand the study procedures and provide voluntary written informed consent.\n\nExclusion Criteria:\n\n* Medical conditions that contraindicate participation in rehabilitation exercise, as determined by the attending physician.\n* Severe cognitive impairment or communication difficulties that interfere with understanding or following study instructions.\n* Unstable medical conditions requiring ongoing intensive medical treatment.\n* Inability to use a smartphone or digital platform independently.\n* Refusal to participate or withdrawal of informed consent.",{"count":398,"type":21},70,[159],"This study aims to evaluate the feasibility, usability, and clinical effectiveness of a digital rehabilitation platform in adult patients discharged from the intensive care unit (ICU). Adult patients aged 19 years or older who stayed in the ICU for more than 48 hours and are capable of using a smartphone will be enrolled from two tertiary hospitals in South Korea.\n\nParticipants will receive individualized rehabilitation programs using a digital rehabilitation platform (\"Tuntun Rehabilitation Assistant\") based on their functional status. Rehabilitation will be conducted once daily for up to 30 minutes per session. Physical and cognitive function outcomes will be assessed at baseline, two weeks after intervention initiation, at hospital discharge, and during follow-up when applicable.\n\nThis prospective cohort study will investigate changes in physical function, mobility, cognitive status, and quality of life, as well as platform usage and safety-related events, to determine the clinical usefulness of digital rehabilitation for ICU survivors.",[402],"ICU Acquired Weakness (ICUAW)",[404,405],"Intensive Care Unit Acquired weakness","Digital Therapeutics","2026-03-19",{"date":408,"type":36},"2026-03-23",{"date":410,"type":36},"2026-02-02",{"date":342,"type":21},{"name":42,"class":43},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":85,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":150},"100593750","phase-2-a-prospective-study-to-evaluate-the-safety-and-efficacy-of-the-combination-therapy-of-irpagratinib-atezolizumab-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-100593750","NCT07010497","A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma","A PHASE 2, OPEN-LABEL STUDY OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (IAPETUS)","IAPETUS","Inclusion Criteria:\n\n* 1.Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.\n* 2.Male or female, aged ≥19 at the time of signing inform consent form.\n* 3.Patients must have histological or cytological confirmed advanced or unresectable HCC not amenable to curative surgical or loco-regional therapies. And patients must satisfy:\n\n  1. Provide archived tissue sample for FGF19 overexpression detection.For Safety-Run in and Expansion: the result of FGF19 overexpression lab testing must be positive as defined. Only tissue from primary lesion of liver is eligible.\n  2. Barcelona Clinic Liver Cancer (BCLC) stage B or C and Child-Pugh score 5\\~6 without hepatic encephalopathy, no clinically apparent ascites or require medical intervention.\n  3. Have at least 1 target lesion (per RECIST v1.1). Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous injection, cryoablation, high-intensity focused ultrasound, transarterial (chemo) embolization, etc.) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed per RECIST v1.1.\n* 4.ECOG performance status score 0-1\n* 5.Life expectancy ≥ 3 months\n* 6.Adequate organ and hematologic function as indicated by the following screening assessments performed within 14 days prior to the first administration (without blood transfusion, or medication with stimulation factors or thrombopoietin receptor agonists (TPO-RAs) within 14 days before blood sample collection):a) Absolute neutrophil count (ANC) ≥1.0×109\u002FLb) Platelet count (PLT) ≥75×109\u002FLc) Hemoglobin (Hb) ≥85g\u002FL (8.5g\u002FdL)d) Total bilirubin (TBIL) ≤3×ULNe) Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 5 ×ULNf) Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Crcl) ≥50 mL\u002Fmin based on Cockcroft-Gault formulag) For patients not receiving therapeutic anticoagulation: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤2×ULN.h) Urinalysis for proteinuria \\\u003C2+ (patients discovered to have ≥2+ proteinuria on urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\\u003C1g of protein in 24 hours)\n* 7.Non-surgically sterilized male or female patients of childbearing potential must agree to use effective methods of birth control during the study and for up to 6 months after the last dose of study drug. Non-surgically sterilized female patients of childbearing potential must in non-lactation period and have a negative β-HCG test result within 14 days before first administration.\n\nExclusion Criteria:\n\nPrior\u002FConcomitant Therapy\n\n* 1\\. Has received any systemic chemotherapy, including anti-VEGF therapy, or any systemic investigational anticancer agents for advanced\u002Funresectable HCC. Patient who has received one cycle of Atezolizumab plus Bevacizumab is eligible for this trial.\n* 2\\. Has received prior therapy with immune checkpoint inhibitors or immune stimulatory agents (eg, anti-PD-1, anti-PD-L1\u002F2, anti-CTLA-4, anti-TIGIT, OX-40, or CD137). Patients has received one cycle of Atezolizumab plus Bevacizumab is eligible for this trial.\n* 3\\. Previous treatment with FGFR inhibitors including selective FGFR4 or pan-FGFR inhibitors.\n* 4\\. Has received locoregional therapy to liver (transcatheter chemoembolization, transcatheter embolization, hepatic arterial infusion, radiation, radioembolization, or ablation) within 4 weeks prior to the first dose of study intervention.\n* 5\\. Previous anti-cancer therapy prior to initiation of study treatment: major surgery (except palliative therapy), radiotherapy (bone-marrow exposure \\>30%), loco-regional treatment \\\u003C4 weeks; endocrine therapy with anti-tumor indications for \\\u003C 2 weeks.\n* 6\\. Prior toxicities from radiotherapy and other anti-cancer therapies that have not recovered to Grade ≤1 (CTCAE v5.0) except for which eligibility criteria allowed, alopecia, vitiligo, hormone replacement therapy controlled stable hypothyroidism, and Grade ≤2 neurotoxicity or toxicities related to prior one cycle of Atezolizumab plus Bevacizumab that investigator believes don't affect patients and safety assessment.\n* 7\\. Concomitant use of P-gp transporter inhibitors; as well as moderate or strong inhibitors or inducers of CYP3A4 (including grapefruit juice, grapefruit hybrids, pomegranates, starfruits, pomelos, Seville oranges or juice or products) within at least 14 days prior to the first dose of the study drug.\n* 8\\. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to initiation of study treatment, or anticipated requirement for systemic immunosuppressive medications during the trial (except for patients who received one-time, acute, low-dose prednisone \\\u003C7.5 mg\u002Fd or equivalent corticosteroids).\n* 9\\. Vaccination with a live, attenuated vaccine within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines).\n* 10\\. Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID). Occasional use of NSAIDS for the symptomatic relief of medical conditions such as headache or fever is allowed.\n* 11\\. Active infection or unexplained fever \\> 38.5℃ or last treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to the first dose of study treatment.\n\nFactors related to the disease\n\n* 12\\. Known fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.\n* 13\\. Has a known active central nervous system (CNS) metastasis.\n* 14\\. Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses (\\\u003C30 mm from the carina) of large volume. Patients with vascular invasion of the portal or hepatic veins may be enrolled.\n* 15\\. Patients with refractory\u002Funcontrolled ascites, pleural effusion or pericardial effusion requiring intervention within 2 weeks before administration of study treatment.\n* 16\\. History of hepatic encephalopathy.\n* 17\\. Liver tumor as a percentage of liver ≥ 50% as judged by the investigator.\n* 18\\. Vp4 type portal vein tumor thrombus and beyond (such as inferior vena cava).\n* 19\\. Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high risk for bleeding or a prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment.\n* 20\\. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to the first dose of Bevacizumab.\n* 21\\. History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment.\n\nDiagnostic Assessments\n\n* 22\\. History of second primary malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, etc.\n* 23\\. Known allergy or hypersensitivity to any component of the investigational drug product formulation or history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins. Known hypersensitivity to Chinese hamster ovary cell products.\n* 24\\. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, etc. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) that don't require systemic treatment are eligible for the study. For uncertain autoimmune disease, it could be discussed with the sponsor.\n* 25\\. Prolongation of QTcF (\\> 470 ms \\[average of three ECGs\\], QTc interval corrected by Frederica's formula, QTcF=QT\u002FRR0.33) at screening, and other ECG abnormalities with clinical significance by the judge of the investigator and affect the patient's safety assessment.\n* 26\\. Left ventricle ejection fraction\\\u003C50%.\n* 27\\. Impaired cardiac function or clinically significant cardiac disease, including but not limit to any one of the following: New York Heart Association class III or IV congestive heart failure, unstable angina, or myocardial infarction within 6 months before administration of the study drug. Any cardiac arrhythmia requiring treatment or intervention. Uncontrolled hypertension (Systolic blood pressure≥150mmHg and\u002For diastolic blood pressure≥100mmHg).\n* 28\\. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to initiation of study treatment.\n* 29\\. Any serious acute or chronic infection requiring systemic anti-infective therapy (except for viral hepatitis, see exclusion criteria 31-33).\n* 30\\. History of immunodeficiency, including HIV antibody serum test positive, or other acquired\u002Fcongenital immunodeficiency disease, or active tuberculosis.\n* 31\\. Patients with HBV infection should follow local clinical practice and anti-HBV therapy should be performed to ensure adequate viral suppression. HBV-DNA ≥2000 IU\u002FmL (or equivalent copies\u002FmL) obtained within 14 days prior to initiation of study treatment.\n* 32\\. Patients with HBV and HCV co-infection. If there is only a history of HCV infection, but HCV RNA (-), it is not regarded as HCV infection.\n* 33\\. Patients with active HCV infection (HCV-RNA\\>103 copies\u002FmL or following local clinical practice) or require concomitant anti-HCV therapy during the study.\n* 34\\. Any other clinically significant comorbidities, such as respiratory, metabolic, congenital, endocrine or central nervous system disease, or any other medical conditions, mental disturbances or social determinants, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.\n\nOther Exclusions\n\n* 35\\. History of allogeneic stem cell transplantation or organ transplantation.\n* 36\\. History of hemoptysis (≥2.5mL of bright red blood per episode) within 1 month prior to initiation of study treatment.\n* 37\\. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).\n* 38\\. Current or recent (within 10 days prior to study treatment start) use of aspirin (\\>325 mg\u002Fday) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.\n* 39\\. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anti-coagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose.\n* 40\\. Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR\\\u003C1.5×ULN and APTT is within normal limits within 14 days prior to initiation of study treatment.\n* 41\\. For prophylactic use of anti-coagulants or thrombolytic therapies, local label approved dose levels may be used.\n* 42\\. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.\n* 43\\. Inability to take oral medication or other factors significant preclude adequate absorption of oral medication, such as previously received total gastrectomy, residual gastric dysfunction after subtotal gastrectomy, short bowel syndrome after small bowel resection, active diarrhea or severe irritable bowel syndrome required drug treatment, etc.",{"count":96,"type":21},[131],"This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression.\n\nThis study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.",[425],"Carcinoma, Hepatocellular","2026-03-17",{"date":428,"type":36},"2026-03-18",{"date":430,"type":36},"2026-03-16",{"date":432,"type":21},"2029-03-31",{"name":42,"class":43},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":85,"phases":443,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":455,"locationsCount":150},"100557367","abbreviated-mri-using-gadoxetic-acid-versus-ct-for-surveillance-of-recurrent-hcc-after-curative-treatment-100557367","NCT06537193","Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment","A Prospective Multicenter Study for the Intra-Individual Comparison of Abbreviated MRI Using Gadoxetic Acid and Dynamic CT for Surveillance of Recurrent HCC After Curative Treatment","Inclusion Criteria:\n\n1. Patients with more than two years without recurrence after curative treatment (surgery or local ablation) for HCC\n2. Patients with no history of systemic treatment, radiation therapy, or trans-arterial chemoembolization for HCC\n3. Older than 20 years of age\n4. Eastern Cooperative Oncology Group performance status of 0-2\n5. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures\n6. Patient is willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Active or suspected cancer, or a history of malignancy where the risk of recurrence is equal or higher than 20% within 2 years.\n2. Significant medical comorbidities in which survival is predicted to be less than 3 years\n3. Estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m²\n4. Child-Pugh class C\n5. Patient not eligible for applying LI-RADS criteria, such as Budd-Chiari Syndrome\n6. Previous history of severe allergic reaction to iodine contrast medium\n7. Precautions for MRI (cardiac pacemaker, severe claustrophobia that may interfere with protocol compliance).\n8. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with completing the study.",{"count":442,"type":21},455,[159],"Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising to 80% after ablation therapy. This is partly because underlying cirrhosis or chronic liver disease remains, increasing the risk of secondary HCC. The risk of recurrence varies over time, with a high risk in the first two years due to micro-metastasis. Later recurrences are usually new primary cancers (de novo HCC). Therefore, regular imaging tests, such as computed tomography (CT) or magnetic resonance imaging (MRI) every three months in the first two years, are necessary for early detection, but guidelines for post-two-year screenings are unclear.\n\nCurrently, for patients recurrence-free for two years, contrast-enhanced liver CT or MRI is performed every 3-6 months as a secondary screening test. However, repeated use of CT raises concerns about radiation exposure and iodine-based contrast agents can lead to side effects and kidney issues. MRI with hepatocyte-specific agents like gadoxetic acid (Primovist) is effective but costly and time-consuming, with potential side effects from repeated gadolinium exposure. Therefore, there is a need for a validated secondary screening method that is both effective and reduces patient risk.\n\nAbbreviated contrast-enhanced MRI, using only essential sequences, has shown promise in retrospective studies for detecting HCC. However, these studies have limitations, such as potential bias and lack of data on repeated screenings. There is limited research on secondary screening post-curative treatment for HCC. This study aims to prospectively evaluate the use of abbreviated contrast-enhanced MRI with Primovist as a secondary screening method for detecting secondary HCC in patients who have been recurrence-free for more than two years.",[136],[447,448],"Abbreviated MRI","Dynamic CT","2026-03-08",{"date":451,"type":36},"2026-03-10",{"date":453,"type":36},"2024-12-12",{"date":73,"type":21},{"name":42,"class":43},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":85,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":479},"100626140","phase-4-comparison-of-anti-thrombotic-treatments-between-aspirin-and-warfarin-during-initial-six-months-after-bioprpsthetic-heart-valve-replacement-100626140","NCT07431762","Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","CONCLAVE","Inclusion Criteria:\n\n1. Aged ≥ 19 years with successful surgical bioprosthetic valve replacement\n2. Bioprosthetic heart valve in aortic or mitral valve positions, for a day postoperatively\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Mechanical valve in any heart valve position\n2. Previous hemorrhagic stroke within the last 3 months\n3. Clinically overt stroke within the last 3 months\n4. Current need for anticoagulation (i.e. atrial fibrillation, deep vein thrombosis)\n5. Unstable postoperative conditions at index point (i.e. requirement mechanical hemodynamix support, disabling complications, stroke \\[ischemic, embolic\\], hemorrhagic stroke)\n6. Hypersensitivity to the main component or constituents of aspirin or vitamin K antagonist\n7. Pregnant or lactating women",{"count":464,"type":21},1058,[87],"This trial is a multinational, multicenter, randomized, open-label, active-controlled clinical trial comparing the safety of aspirin versus vitamin K antagonists (warfarin) as oral antithrombotic therapy during the initial 6 months following tissue valve replacement (aortic or mitral).",[468],"Valve Replacement Surgery",[470],"aspirin versus vitamin K antagonists","2026-02-20",{"date":473,"type":36},"2026-02-25",{"date":475,"type":21},"2026-02-01",{"date":477,"type":21},"2031-03-31",{"name":42,"class":43},3,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":85,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":150},"100615681","atrial-fibrillation-detection-using-memo-patch-in-patients-with-stroke-of-unknown-cause-100615681","NCT07295769","Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause","Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause: A Single-Center, Prospective, Exploratory Trial to Validate the Efficacy and Safety of Noninvasive Long-Term Electrocardiographic Monitoring","Inclusion Criteria:\n\nParticipants may take part in this clinical study only if they meet all of the following criteria:\n\n1. Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study\n2. Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source)\n3. Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria cannot be enrolled in this clinical study:\n\n1. Individuals already diagnosed with atrial fibrillation or atrial flutter\n2. Individuals with a clearly identified cause of stroke\n3. Individuals known to have allergic reactions to adhesives or hydrogels\n4. Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation\n5. Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation",{"count":488,"type":21},100,[159],"The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.",[492],"Embolic Stroke of Undetermined Source","2026-02-04",{"date":495,"type":36},"2026-02-06",{"date":497,"type":36},"2026-01-28",{"date":499,"type":21},"2029-02-15",{"name":42,"class":43},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":508,"targetDuration":510,"studyType":22,"phases":4,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":150},"100622352","prospective-cohort-study-of-minimal-residual-diseasemrd-testing-for-early-recurrence-detection-in-endometrial-and-cervical-cancer-100622352","NCT07382505","Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer","Prospective Cohort to Evaluate the Prognostic and Early-Recurrence Detection Performance of Blood-based Minimal Residual Disease (MRD) Testing in Endometrial and Cervical Cancer","Inclusion Criteria:\n\n* Histologically confirmed endometrial cancer or cervical cancer.\n* Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT).\n* Provision of written informed consent for study participation and biospecimen collection\n\nExclusion Criteria:\n\n* Synchronous other malignancies (cancer requiring treatment within the last 5 years).\n* Persistent infection or bleeding tendency that makes repeated blood collection unsafe.\n* Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).\n* Any condition that the principal investigator deems inappropriate for the study.",{"count":509,"type":21},600,"2 Years","This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a \"lead time\"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.",[513,514],"Uterine Neoplasms","Cervical Cancer",[516,514,63,64,517,65],"Endometrial Cancer","Circulating Tumor DNA","2026-01-27",{"date":410,"type":36},{"date":521,"type":21},"2026-02-15",{"date":229,"type":21},{"name":42,"class":43},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":85,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":150},"100617088","phase-2-18ffes-petct-for-the-detection-of-distant-metastasis-in-low-grade-er-positive-stage-iii-breast-cancer-100617088","NCT07314073","[18F]FES PET\u002FCT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer","A Phase 2, Open-label, Non-randomized, Single Center Study Evaluating 18F-Fluoroestradiol Positron Emission Tomography\u002FComputed Tomography for the Detection of Distant Metastases in Low-grade, Estrogen Receptor-positive Stage III Breast Cancer","Inclusion Criteria:\n\n1. Male or female patients aged ≥19 years, regardless of race\u002Fethnicity\n2. Patients newly diagnosed with invasive breast cancer within 90 days prior to screening, with documented histopathological confirmation.\n3. Patients diagnosed with histologically confirmed estrogen receptor-positive, histologic grade 1 or 2 primary breast cancer\n4. Patients with clinical stage IIIA-IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system\n5. Patients who have undergone, or are scheduled to undergo chest computed tomography (CT), abdominal CT, and bone scintigraphy within 90 days prior to screening before the 18F-FES PET\u002FCT scan\n6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤2\n\nExclusion Criteria:\n\n* The subject or the subject's legally authorized representative has not signed the informed consent form\n* Subjects who are currently receiving systemic therapy for breast cancer (e.g., neoadjuvant chemotherapy, hormonal therapy)\n* Subjects with a history of another invasive malignancy within the past 2 years (except for non-melanoma skin cancer)\n* Subjects diagnosed with distant metastases on chest CT, abdominal CT, or bone scintigraphy performed within 90 days prior to screening or before the 18F-FES PET\u002FCT scan\n* Subjects for whom neither biopsy nor ≥6 months of follow-up imaging has been performed for lesions suspicious for distant metastases\n* Pregnant or breastfeeding women. The following cases are considered not at risk of pregnancy: (1) physiologically postmenopausal (no menses for ≥2 years), (2) surgically sterile (history of bilateral oophorectomy or hysterectomy), (3) women of childbearing potential with a documented negative serum or urine pregnancy test within 24 hours prior to 18F-FES administration, and who agree to use effective contraception during the trial.\n* Subjects with serious and\u002For uncontrolled and\u002For unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic kidney disease, or chronic liver disease)\n* Subjects who are relatives or students of the investigator, or otherwise in a dependent relationship with the investigator\n* Subjects who, in the judgment of the investigator, are unable to provide complete data for the clinical trial due to personal circumstances or other reasons",{"count":532,"type":21},85,[131],"This study aims to evaluate the detection rate of distant metastases using \\[18F\\]FES PET\u002FCT in patients with low-grade, ER-positive stage III breast cancer.",[536],"Stage III Breast Cancer",[538,539,540,541],"breast cancer","estrogen receptor","[18F]FES PET\u002FCT","distant metastasis","2025-12-23",{"date":544,"type":36},"2026-01-02",{"date":546,"type":36},"2025-12-24",{"date":40,"type":21},{"name":42,"class":43},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":85,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":150},"100617083","left-bundle-branch-versus-minimized-ventricular-pacing-in-patients-with-sick-sinus-syndrome-and-prolonged-av-interval-100617083","NCT07314008","Left Bundle Branch Versus Minimized Ventricular Pacing in Patients With Sick Sinus Syndrome and Prolonged AV Interval","Comparison of Left Bundle Branch Area Pacing and Minimized Ventricular Pacing in Patients With Sinus Node Dysfunction and Atrioventricular Conduction Delay: A Multicenter, Randomized Controlled Clinical Trial","CLOSE-AV","Inclusion Criteria:\n\n* \\>18 years old\n* Sinus node dysfunction with symptoms\n* Atrioventricular conduction delay (PR interval \\> 200ms)\n\nExclusion Criteria:\n\n* Subject was unable to provide written informed consent or participate in long-term follow-up.\n* Permanent atrial fibrillation\n* Pre-existing cardiac implantable electronic device\n* Persistent advanced atrioventricular conduction disturbance (2:1 block, Mobitz type II, or 3rd degree)\n* Mechanical tricuspid valve\n* Ventricular septal defect or scar\n* Left ventricular ejection fraction \\\u003C 35% who indicated cardiac resynchronization therapy\n* Previous heart transplantation\n* Pregnant and\u002For lactating women\n* Life expectancy \\\u003C2 year\n* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period",{"count":558,"type":21},440,[159],"The goal of this clinical trial is to compare two pacemaker strategies: Left Bundle Branch Area Pacing (LBBAP) and Minimized Ventricular Pacing (MVP) in patients requiring a permanent pacemaker for sick sinus syndrome and prolonged AV interval. It will also evaluate the safety and feasibility of the LBBAP method in these patients.\n\nThe main questions it aims to answer is:\n\n\\*Is LBBAP with physiological AV interval better than Minimized Ventricular Pacing?\n\nResearchers will compare the LBBAP group (aiming for conduction system capture with physiological AV intervals) to the MVP group (aiming to minimize ventricular pacing with prolonged AV intervals) to evaluate the optimal pacing strategy.\n\nParticipants will:\n\n* Be randomly assigned to either the LBBAP group or the MVP group.\n* Undergo a pacemaker implantation procedure according to the specific criteria for their assigned group.\n* Visit the clinic for regular checkups to measure pacing function and ensure the device settings remain compliant with the study protocol.",[562,563],"Sick Sinus Syndrome","Atrioventricular Nodal Dysfunction",{"date":544,"type":36},{"date":566,"type":36},"2025-05-02",{"date":568,"type":21},"2029-01-31",{"name":42,"class":43},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":85,"phases":579,"briefSummary":580,"conditions":581,"keywords":584,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":4},"100615632","phase-2-rescue-study-recurrent-ovarian-cancer-secondary-cytoreduction-using-chemotherapy-response-100615632","NCT07295132","RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)","A Randomized Clinical Trial Evaluating the Role of Secondary Cytoreductive Surgery Following Neoadjuvant Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: Patient Selection Informed by CA-125 Response Dynamics During Chemotherapy (RESCUE Study)","Inclusion Criteria:\n\n* First recurrence of platinum-sensitive, invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of initial stage.\n* A progression-free interval of at least 6 months after the end of the last platinum-containing regimen.\n* Demonstrated response during neoadjuvant chemotherapy after recurrence (Complete Response\u002FPartial Response\u002FStable Disease according to RECIST 1.1 or GCIG CA-125 response, which is a ≥50% reduction in pre-treatment CA-125 level sustained for ≥28 days).\n* Women aged 19 years or older.\n* The tumor is judged to be completely resectable by surgery (R0) based on the judgment of an experienced surgeon\n* Patients who provide signed and written informed consent and consent to data transfer and processing.\n\nExclusion Criteria:\n\n* Patients without recurrence\n* Patients with non-epithelial tumors or borderline tumors.\n* Patients with second, third, or subsequent recurrence.\n* Patients with a secondary malignancy treated with laparotomy and other neoplasms, where the treatment is expected to interfere with the treatment of recurrent ovarian cancer or significantly affect prognosis.\n* Patients with platinum-refractory tumors (i.e., progression during chemotherapy or recurrence within 6 months after the end of the previous first platinum-containing regimen).\n* Cases where only palliative surgery is planned.\n* Radiological signs suggestive of metastasis that are considered completely unresectable.\n* Any comorbidity that precludes surgery and\u002For chemotherapy (e.g., poor general condition, severe infection, conditions that may cause severe bleeding, severe renal disease, etc.).\n* Any medical history that may cause excessive surgical risk pre- or post-operatively.\n* Medications being taken that pose a significant surgical risk (e.g., oral anticoagulants, bleeding risk due to bevacizumab).\n* Absence of evaluable archived tumor tissue.",{"count":578,"type":21},160,[131],"This is a multicenter, prospective, randomized, open-label Phase III clinical trial (RESCUE study) evaluating the efficacy of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have shown a favorable response to 3-4 cycles of platinum-based neoadjuvant chemotherapy and are assessed as highly likely to achieve complete tumor resection based on selection models. Eligible patients will be randomly assigned to either the experimental arm, receiving SCS followed by chemotherapy (with or without maintenance), or the active comparator arm, receiving chemotherapy only (with or without maintenance), with the primary objective being to compare the Progression-Free Survival (PFS) between the two groups to determine the additional clinical benefit of SCS in this carefully selected patient population.",[582,583],"Ovarian Cancer Recurrent","Platinum Sensitive Ovarian Cancer",[585,586,587,588],"platinum sensitive recurrent ovarian cancer","secondary cytoreductive surgery","neoadjuvant chemotherapy","CA-125 response","2025-12-16",{"date":591,"type":36},"2025-12-19",{"date":593,"type":21},"2025-12-15",{"date":595,"type":21},"2029-11-15",{"name":42,"class":43},""]